Multidrug-resistant Acinetobacter baumannii, Russia

Content Provider	Semantic Scholar
Author	Naas, Thierry Kernbaum, Serge Allali, Sophie Nordmann, Patrice L.
Copyright Year	2007
Abstract	Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 4, April 2007 669 levels of susceptibility because the MIC50 was only 1 dilution below the current breakpoint (7,8). Aztreonam resistance could not be transferred by conjugation between IMP-1–producing (aztreonam-resistant) P. putida and P. aeruginosa (2) and is not associated with a transposon carrying blaVIM-2 (6). No evidence of extended-spectrum β-lactamases was detected in our isolates by classic synergy assays with clavulanate plus aztreonam, ceftazidime, or cefotaxime. VIM6–producing P. putida isolates from Singapore (9) were more resistant to aztreonam (MIC >128 μg/mL), ceftazidime, and cefepime (MIC >256 μg/mL). Detection of blaVIM-2 in Pseudomonas in South America was initially reported by the SENTRY Antimicrobial Surveillance Program (10) and included 1 P. fluorescens isolate in Chile and 3 P. aeruginosa isolates in Venezuela. To the best of our knowledge, our report is the first of VIM-2 in P. putida in Latin America. VIM-2–producing P. putida, which were originally restricted to East Asia and only very recently found in France, may represent an emerging pathogen or function as reservoirs for resistance because of their widespread presence in the hospital environment.
Starting Page	669
Ending Page	671
Page Count	3
File Format	PDF HTM / HTML
PubMed reference number	17561578v1
Volume Number	13
Journal	Emerging infectious diseases
Alternate Webpage(s)	https://wwwnc.cdc.gov/eid/article/13/4/pdfs/06-0755.pdf
Language	English
Access Restriction	Open
Subject Keyword	Aztreonam Cefotaxime Ceftazidime Ceramide Dodecasaccharide Clavulanate Dermox Hospitals Infectious Disease Medicine Oriental Medicine Pathogenic organism cefepime
Content Type	Text
Resource Type	Article